Torrent Pharma to trim combined sales force to about 9,000 as JB Pharma integration advances
Torrent Pharmaceuticals is consolidating JB Pharma’s field force, brands and distribution network after acquiring a controlling stake. Medical-representative strength is expected to fall from about 9,400 to 9,000, with brand and territory transfers likely to create temporary revenue disruption for two to three quarters.
Torrent Pharma is integrating JB Pharma’s brands, field force and distribution network, reducing combined MRs to about 9,000. Brand and territory transfers may temporarily affect Indian revenues for two to three quarters, while management targets faster-than-expected merger synergies.
Why this matters
The consolidation follows Torrent Pharma's Q1 revenue rising 55% after the JB Pharma acquisition, while PAT rose 3.3% amid integration costs. Another recent signal cited domestic demand lifting Torrent in the June quarter.
Retail-company signals are accelerating, up +259300% QoQ.